Adverse events associated with immune checkpoint inhibitor treatment for cancer
Open accessAbstract
Key points Inhibitors against cytotoxic T-lymphocyte–associated protein 4 and programmed cell death 1 immune checkpoints are novel agents that modulate immune pathways and enhance anti-tumour immunity. Their use has set new standards in the treatment of many cancer types. Some patients with
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The lack of specificity of ICIs is responsible for immune-related adverse events (irAEs).
“The lack of specificity of ICIs is, on the other hand, responsible for undesirable off-target immune and inflammatory events known as immune-related adverse events (irAEs)2.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works
Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., Ripke, S., Lee, J. C., Jostins, L., Shah, T., et al. (2015) · Nature Genetics · doi:10.1038/ng.3359 · Cited by 2,603 · see citing works
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · see citing works
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · see citing works
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2925 · Cited by 1,003 · see citing works
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · see citing works
Gettinger, S. N., Horn, L., Jackman, D. M., Spigel, D. R., Antonia, S. J., Hellmann, M. D., Powderly, J. D., Heist, R. S., Sequist, L. V. D., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 740 · see citing works
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · see citing works
Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655 · see citing works
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487 · see citing works
Abdel‐Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160221 · Cited by 442 · see citing works
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431 · see citing works
Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.019 · Cited by 377 · see citing works
Kostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., Dousset, L., Pham‐Ledard, A., Prey, S., Beylot-Barry, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212257 · Cited by 307 · see citing works
Anti-CTLA4 Antibody–Induced Lupus Nephritis
Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300 · see citing works
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes
Lühder, F., Höglund, P., Allison, J. P., Benoist, C. O., & Mathis, D. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.427 · Cited by 290 · see citing works
Sznol, M., Ferrucci, P. F., Hogg, D., Atkins, M. B., Wolter, P., Guidoboni, M., Lebbé, C., Kirkwood, J. M., Schachter, J., Daniels, G. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1167 · Cited by 289 · see citing works
Diehl, A., Yarchoan, M. M., Hopkins, A., Jaffee, E. M., & Grossman, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23217 · Cited by 247 · see citing works
Belkhir, R., Burel, S. L., Dunogeant, L., Marabelle, A., Hollebecque, A., Besse, B., Leary, A. F., Voisin, A.-L., Pontoizeau, C., Coutte, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211216 · Cited by 244 · see citing works
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Klocke, K., Sakaguchi, S., Holmdahl, R., & Wing, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603892113 · Cited by 232 · see citing works
Gutzmer, R., Koop, A., Meier, F. E., Hassel, J. C., Terheyden, P. A. M., Zimmer, L., Heinzerling, L., Ugurel, S., Pföhler, C., Gesierich, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.038 · Cited by 204 · see citing works
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Esfahani, K., & Miller, W. H. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703047 · Cited by 200 · see citing works
Self-citationSuh, K. J., Kim, S. H., Kim, Y. J., Kim, M., Keam, B., Kim, T. M., Kim, D., Heo, D. S., & Lee, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2092-x · Cited by 170 · see citing works
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Shoushtari, A. N., Friedman, C. F., Navid-Azarbaijani, P., Postow, M. A., Callahan, M. K., Momtaz, P., Panageas, K. S., Wolchok, J. D., & Chapman, P. B. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2391 · Cited by 157 · see citing works
Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 129 · see citing works
Sato, K., Akamatsu, H., Murakami, E., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., Nakanishi, M., & Yamamoto, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx697.052 · Cited by 48 · see citing works
Ipilimumab-induced colonic perforation
Burdine, L. J., Lai, K., & Laryea, J. A. (2014) · Journal of Surgical Case Reports · doi:10.1093/jscr/rju010 · Cited by 28 · see citing works
Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis
Desforges, P., Esfahani, K., & Bouganim, N. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.024992 · Cited by 5 · see citing works
Self-citationIpilimumab-Induced Colonic Perforation
Haider, A., & O’Riordan, K. (2014) · The American Journal of Gastroenterology · doi:10.14309/00000434-201410002-01425 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Raschi, E., Gatti, M., Gelsomino, F., Ardizzoni, A., Poluzzi, E., & De Ponti, F. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00738-6 · Cited by 157 · see citing works
Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109 · see citing works
Self-citationThyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 81 · see citing works
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 81 · see citing works
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 63 · see citing works
Self-citationThyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 61 · see citing works
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
Joseph, G. J., Johnson, D. B., & Johnson, R. W. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100505 · Cited by 53 · see citing works
Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma
Claveau, J., Archambault, J., Ernst, D. S., Giacomantonio, C. A., Limacher, J. J., Murray, C. S., Parent, F., & Zloty, D. M. (2020) · Current Oncology · doi:10.3747/co.27.6015 · Cited by 51 · see citing works
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 47 · see citing works
Lin, A., Huang, L., Jiang, A., Zhu, L., Mou, W., Li, Y., Zhang, C., Liu, Z., Zhang, J., Cheng, Q., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04183-y · Cited by 46 · see citing works
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges
Bandara, S., & Raveendran, S. (2025) · Cancers · doi:10.3390/cancers17050821 · Cited by 46 · see citing works
Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer
Manz, S., Losa, M., Fritsch, R., & Scharl, M. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211002018 · Cited by 33 · see citing works
Lung Cancer and Interstitial Lung Diseases
Drakopanagiotakis, F., Krauss, E., Michailidou, Ι., Drosos, V., Anevlavis, S., Guenther, A., & Steiropoulos, P. (2024) · Cancers · doi:10.3390/cancers16162837 · Cited by 31 · see citing works
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 28 · see citing works
Nasca, V., Barretta, F., Corti, F., Lonardi, S., Niger, M., Élez, E., Fakih, M., Jayachandran, P., Shah, A. T., Salati, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005493 · Cited by 29 · see citing works
Duttagupta, S., Hakozaki, T., Routy, B., & Messaoudene, M. (2023) · Current Oncology · doi:10.3390/curroncol30110681 · Cited by 27 · see citing works
Bardoscia, L., Pasinetti, N., Triggiani, L., Cozzi, S., & Sardaro, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.746853 · Cited by 27 · see citing works
Gemcitabine‐Loaded Injectable Hydrogel for Localized Breast Cancer Immunotherapy
Barough, M. S., Seyfoori, A., Askari, E., Mahdavi, M., Sarrami‐Forooshani, R., Sadeghi, B., Kazemi, M. H., Falak, R., Khademhosseini, A., Mojtabavi, N., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202403910 · Cited by 23 · see citing works
Bedke, J., Black, P. C., Szabados, B. E., Guerrero‐Ramos, F., Shariat, S. F., Xylinas, E. N., Brinkmann, J., Blake-Haskins, J. A., Cesari, R., & Palou, J. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.10.004 · Cited by 21 · see citing works
Adverse Renal Effects of Anticancer Immunotherapy: A Review
Borówka, M., Łącki-Zynzeling, S., Nicze, M., Kozak, S., & Chudek, J. T. (2022) · Cancers · doi:10.3390/cancers14174086 · Cited by 19 · see citing works
Liu, J., Pan, D., Huang, X., Wang, S., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225483 · Cited by 19 · see citing works
Ma, C., Pai, R. K., Schaeffer, D. F., Krell, J., Guizzetti, L., McFarlane, S. C., MacDonald, J. K., Choi, W., Feakins, R. M., Kirsch, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004560 · Cited by 17 · see citing works
Druce, I., Tawagi, K., Shaw, J. L. V., Ibrahim, A. M., Lochnan, H. A., & Ong, M. (2022) · Current Oncology · doi:10.3390/curroncol29070370 · Cited by 16 · see citing works
Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment
Sundarrajan, C., Bhai, S. F., & Dimachkie, M. M. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/q7mdjs · Cited by 14 · see citing works
Lui, D. T. W., Lee, C., Tang, V., Fong, C. H. Y., Lee, A. C. H., Chiu, J. W. Y., Leung, R. C. Y., Kwok, G. W., Li, B. C. W., Cheung, T. T., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.017 · Cited by 14 · see citing works
A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen
Yin, J., Wen, M., Cheng, J., Hu, L., Yang, L., Chang, X., Zhou, Z., Li, H., Liu, Y., & Li, J.-B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.712466 · Cited by 13 · see citing works
Immune checkpoint inhibitors in kidney transplantation
Alzahrani, N., Jurdi, A. A., & Riella, L. V. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001036 · Cited by 13 · see citing works
Li, Y., Zhou, Y., Liu, Y., Guang-ju, Z., Xiao, L., Li, N., Qin, H., Wang, J.-G., & Zhang, L. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13967 · Cited by 12 · see citing works
Prospects and Challenges of Immunotherapy for Thyroid Cancer
Song, P., Pan, G., Zhang, Y. L., Ni, Y., Wang, Q., Shi, J., Peng, Y., Jing, R., & Luo, D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.012 · Cited by 10 · see citing works
Moldawer, N. P., & Wood, L. S. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000476 · Cited by 10 · see citing works
Enteritis with immune checkpoint inhibitor use
Sanders, D., Webber, D. L., & Chatur, N. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190244 · Cited by 9 · see citing works
Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes
García‐Goñi, M., Gutiérrez, B. V., Sanmamed, M. F., Martín‐Algarra, S., Perez‐Gracia, J. L., Olmedo, M., Chumbiauca, E., Martín‐Calvo, N., & Galofré, J. C. (2024) · Endocrine Related Cancer · doi:10.1530/erc-24-0064 · Cited by 7 · see citing works
Kim, H.-B., Park, S.-G., Hong, R., Kang, S., & Na, Y. S. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i13.2833 · Cited by 7 · see citing works
Ebinama, U., Sheshadri, A., Anand, K., & Iyer, S. P. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-38 · Cited by 6 · see citing works
New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis
Velikova, T. V., Krastev, B. M., Gulinac, M., Zashev, M., Graklanov, V., & Peruhova, M. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i6.1050 · Cited by 6 · see citing works
Yang, G., & Massumi, M. (2025) · Antibodies · doi:10.3390/antib14030052 · Cited by 5 · see citing works
Santo, G., Cucè, M., Restuccia, A., Giudice, T. D., Tassone, P., Cicone, F., Tagliaferri, P., & Cascini, G. L. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00774-9 · Cited by 5 · see citing works
Wilkinson, A. N. (2021) · Canadian Family Physician · doi:10.46747/cfp.6707512 · Cited by 4 · see citing works
Medicinal Mishap: Immune checkpoint inhibitors and immune-related adverse events
Naidoo, W., Cuff, K. E., & Ryan, M. I. (2024) · Australian Prescriber · doi:10.18773/austprescr.2024.039 · Cited by 4 · see citing works
Tumor Immune Cell Targeting Chimeras (TICTACs) reprogram tumor-associated macrophagesPreprint
Morimoto, M., Roberts, D. S., Wen, R. M., Handy, E., Peterson, E. E., Stepek, G. M., Till, N. A., Brooks, J. D., & Bertozzi, C. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.06.570444 · Cited by 4 · see citing works
Tumor immune cell targeting chimeras reprogram tumor-associated macrophages
Morimoto, M., Roberts, D. S., Wen, R. M., Handy, E., Peterson, E. E., Stepek, G. M., Till, N. A., Brooks, J. D., & Bertozzi, C. R. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02258-2 · Cited by 3 · see citing works
Wilkinson, A. N. (2021) · Canadian Family Physician · doi:10.46747/cfp.6707e174 · Cited by 2 · see citing works
Black, P. C., & Eigl, B. J. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02763-z · Cited by 2 · see citing works
Souri, Z., & Pakdel, F. (2024) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v19i3.15047 · Cited by 2 · see citing works
Cervantes‐Torres, J. B., Hernández-Aceves, J. A., Martínez, J. A. G., Moctezuma-Rocha, D., Ramírez, R. V., Sifontes, S., Ramírez-Salinas, G. L., Sierra, L. M., Bonifaz-Alfonzo, L., Sciutto, E., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c07736 · Cited by 2 · see citing works
Chan, S. W. S., Pond, G. R., & Goffin, J. R. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000551 · Cited by 2 · see citing works
Diabetes und onkologische Immuntherapien: Schwerer Autoimmundiabetes durch Immuntherapien möglich
Brandenburg, T., Klose, J. M., Feldkamp, J., & Tan, S. (2025) · Deutsches Ärzteblatt · doi:10.3238/personko.2025.02.07.02 · Cited by 1 · see citing works
Zhao, X., Wang, X., Liu, S., Cheng, P., Chen, J., & Liu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548452 · Cited by 1 · see citing works
Meneses, O., Alzamora, M., Dias, C. A. R., Ortigão, R., & Marques, D. S. (2025) · Cureus · doi:10.7759/cureus.98324 · Cited by 1 · see citing works
Rheumatic manifestations in cancer patients treated with immune checkpoint inhibitors
Janiak, P., Smoleńska, Ż., & Zdrojewski, Z. (2022) · Rheumatology Forum · doi:10.5603/rf.2022.0015 · Cited by 1 · see citing works
Saavedra, C., Mesonero, F., Perna, C., Reguera, P., de la Fuente, E. C., Ferreiro, R., Carrato, A., & Pachón, V. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000922
Rudney, R., & Daeninck, P. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780198837008.003.0022
Toxicidad por inmunoterapia en cáncer: una visión oncológica para el internista
Ahmad-Kanan, A. T., Ordóñez, C., Bermudez, S. D. R., & Corredor-Rengifo, D. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9900
Endocrinopathies Associated with Immune Checkpoint Inhibitors
Druce, I. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1210
Research Progress on Immune Checkpoint Inhibitors Related Liver Injury
何, 元. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.32049
Lin, A., Huang, L., Jiang, A., Zhu, L., Mou, W., Li, Y., Zhang, C., Liu, Z., Zhang, J., Cheng, Q., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5006814
Eichhorn, S., Пили, Р., Epstein, J. B., Rajesh, R., & Satheeshkumar, P. S. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09353-5
Diabetes und onkologische Immuntherapien: Schwerer Autoimmundiabetes durch Immuntherapien möglich
Brandenburg, T., Klose, J. M., Feldkamp, J., & Tan, S. (2025) · Deutsches Ärzteblatt · doi:10.3238/persdia.2025.06.27.01
Talab, T. J., Shafi, F. A. A., & Jasim, S. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.377
Nevrologiske komplikasjoner ved bruk av immunsjekkpunkthemmere
Nes, M. S., Flobak, Å., & Vedeler, C. A. (2025) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.24.0600
Santo, G., Cucè, M., Restuccia, A., Del Giudice, T., Tassone, P., Cicone, F., Tagliaferri, P., & Cascini, G. L. (2024) · Figshare · doi:10.6084/m9.figshare.27049000
Ding, H., 肖向建, Yue, Y., Li, D., Linjing, S., & Lv, P. (2026) · Research Square · doi:10.21203/rs.3.rs-8006056/v1
Хижа, В. В., Козлова, Д. И., Klyaus, N. A., Олегович, К. С., Шолохов, Г. В., Хайманова, Д. Г., Vasiliev, A. A., & Ballyuzek, M. F. (2025) · Medical academic journal · doi:10.17816/maj637360
Fan, T., Wu, L., Lacuo, Z., Liu, Y., & Wu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1722663
Immune-mediated Arthritis after Treatment with Nivolumab in a Patient with Malignant Melanoma
Ivanova, I. (2026) · Rheumatology (Bulgaria) · doi:10.35465/szed3p23
- Authors
- Esfahani, K., Meti, N., Miller, W. H., & Hudson, M.
- Affiliations
- Jewish General Hospital (CA)
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2019-01-13
- Volume
- 191
- Issue
- 2
- Pages
- E40-E46
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- PMC
- PMC6333545
- OpenAlex
- W2908570680
- Cited by
- 65
- References
- 42
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 13 · 2023: 11 · 2022: 9 · 2021: 9 · 2020: 5 · 2019: 2
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Canadian Medical Association Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, adverse events, CTLA-4 inhibitors, PD-1 inhibitors, immune-related adverse events, cancer immunotherapy, antitumor immunity
- MeSH terms
- Antineoplastic Agents, Immunological, Humans, Immune System Diseases, Neoplasms, Cell Cycle Checkpoints, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
